并发静脉癌栓的肾细胞癌中VEGF的表达及临床意义

目的：探讨血管内皮生长因子（VEGF）的表达与肾细胞癌（RCC）并发静脉癌栓（VTT）的关系。方法：采用免疫组织化学MaxVision^TM快捷法检测57例并发或未并发VTT的RCC组织和10例远离肿瘤的正常肾组织中VEGF的表达状况。实验分为三组，A组：并发VTT的RCC组织27例；B组：未并发VTT的RCC组织30例；C组：远离肿瘤的正常肾组织10例。结果：VEGF在三组中的阳性表达率分别为81．5％、63．3％和20．0％，其中A组和C组差异有统计学意义（P〈0．01），A组和B组差异无统计学意义（P〉0．05），B组和C组差异有统计学意义（P〈0．05）。结论：VEGF的异常表达可能在RCC并发VTT的形成中发挥重要作用，以抑制VEGF蛋白及其受体作用的靶向治疗药物在RCC并发VTT的治疗中应有良好效果。

Expression and Clinical Significance of VEGF in Renal Cell Carcinoma with Venous Tumor Thrombus

Objective：To evaluate the relationship between the expression of vascular endothelial growth factor （VEGF） with renal cell carcinoma （RCC） associated with venous tumor thrombus. Methods： The expression of VEGF was detected in 57 cases of RCC with or without venous tumor thrombus and 10 cases of normal renal tissue by immunohistochemical MaxVisionTM fast method. The samples were divided into 3 groups：Group A： renal ceil carcinoma with venous tumor thrombus,n= 27; Group B： renal cell carcinoma without venous tumor thrombus, n= 30; Group C： normal renal tissue remote to the mass of carcinoma, n= 10. Results：In the,three groups, the positive rates of VEGF were 81.5%,63.3% and 20.0% respectively. The expression levels in groups A and B were higher than in group C （P〈0.05）,but there was no significant difference between groups A and group B （P〉0.05）. Conclusions：The abnormal expression of VEGF in RCC may be complicated by the formation of VTT play an important role to inhibit the VEGF protein and its receptor in targeted therapy in the treatment of RCC complicated by VTT should be good results.